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Elephant conservation should always consider 
overall elephant population health and welfare, 
and objectively apply sound science to balance 
health risks and resources to achieve the most 
benefit. While evidence-based medicine is 
increasingly accepted as a sound approach 
for animals and humans, there are substantial 
challenges in conducting rigorous research for 
many of the problems faced by elephants. This 
often results in basing management decisions on 
research studies with designs that have limited 
application to the question at hand. 
The extent to which elephant (population and 
individual) health is affected by TB has not 
been clearly documented, yet in recent years 
large amounts of resources have been spent 
on this specific issue. This is a concern in 
Asian range countries where resources are 
very limited. Elephant health management 
programs that emphasize the risks of a single 
disease without first assessing the risks of other 
health and conservation concerns, relative to 
the benefits of various management strategies, 
will result in misallocation of resources and 
ultimately undermine elephant conservation 
efforts. In other words, disease management 
strategies need to consider ”the big picture”, be 
based on rigorous science, and use transparent 
and objective strategies for balancing risks 
and benefits for various management plans 
and the corresponding allocations of funding. 
Comprehensive assessments of TB, relative to 
other health and conservation challenges, have 
not been conducted for elephants. 
Central concerns since the first recognition of 
TB in elephants include: individual elephant 
Over the past years, periodic meetings to discuss 
various elephant health concerns have been hosted 
in the U.S. These meetings have brought together 
elephant managers, veterinarians, scientists, 
federal and state regulatory veterinarians, public 
health officials, and human infectious disease 
experts. Tuberculosis (TB; mostly Mycobacterium 
tuberculosis in the U.S.) in elephants has been a 
focus of some of these meetings because of its 
high profile and the extensive resources currently 
invested in this issue. Nevertheless, the degree to 
which TB compromises elephant health remains 
unclear; yet large sums of funding are spent on 
the diagnosis, treatment, and management of TB, 
diverting potential resources from conservation.
In the context of Asian elephant conservation, 
managing disease and other health issues calls for 
an assessment of the risks to the species versus the 
allocation of available resources. Epidemiologists 
view disease as the interactions between hosts 
(i.e. immune system function), agents (i.e. TB 
and other infectious and noninfectious causes of 
disease), and the environment. Environmental 
contributions to the development of disease in 
elephants include poor nutritional resources, 
and presumed stress associated with factors such 
as habitat loss, increased habitat sharing with 
domestic animals, and human-elephant conflict. 
Environmental contributions to disease are 
particularly important to consider for free-ranging 
wildlife, including elephants, because they are 
often the most realistic points of intervention for 
disease control in these populations. It is more 
practical to manage the environment to optimize 
elephant health and minimize transmission of 
infectious agents, than it is to treat free-ranging 
elephant populations for diseases such as TB. 
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welfare, occupational risks to those working with 
elephants, and public health risks. These concerns 
present complex challenges. In part, this is due to 
the biology of the organism (a chronic infection 
that is difficult to diagnose); differing viewpoints 
on animal welfare in a dynamic animal welfare 
and animal rights environment; perceived or real 
human health risks; the challenges of developing 
rigorous scientific projects on small populations 
of endangered species; and a complex regulatory 
environment in some countries. Much 
confusion has resulted from debate regarding 
the strengths and weaknesses of various testing 
methods (culture and serology/blood testing); 
incorrect published estimates of TB prevalence; 
uncertainty about effective drugs and side effects 
for elephants with TB; and other factors. This 
confusion is of particular concern where elephant 
or human welfare, and elephant conservation can 
be compromised or limited. 
There is a need for improved information and 
clarity on the key issues. In order to objectively 
and scientifically address concerns about TB, 
professional elephant stakeholders have discussed 
and support the implementation of several focal 
studies, currently underway. Additionally, a 
comprehensive study has been initiated that will 
review animal welfare, experimental design, 
current elephant TB literature, and regulatory 
concerns, with the intent of providing focus to 
future research and TB management guidelines.
Some key points about TB and elephants
* Incorrect information has been presented in the 
literature (e.g. Mikota & Maslow 2011) regarding 
the prevalence of TB in elephants. It has been 
stated that 18% of the U.S. Asian elephant 
population is infected with TB. However, this is 
a cumulative figure that does not use accepted 
epidemiological calculations because it includes 
elephants that are no longer living, while also 
failing to retroactively exclude elephants that 
have been “cleared” of active TB infection post 
treatment. As of January 1, 2012, the prevalence 
of TB in Asian elephants in the U.S. is closer to 
5%. There have been no significant changes in 
the number of newly culture positive animals on 
an annual basis over the past decade, and this 
number corresponds to about one new case per 
year. Consequently, incorrect estimates of the 
percentage of TB infected elephants inaccurately 
skew perceptions and understanding of the actual 
prevalence of active TB infections in elephant 
populations.
* To date, there is no science-based definition of 
“exposure” to differentiate high-risk transmission 
situations for elephants from those with little or 
no risk. There is a gap in knowledge about factors 
that assist in decisions affecting the management 
of TB infected or exposed elephants. To address 
this topic, an epidemiological survey of all 
elephants in the U.S. is currently underway. The 
results of this survey will provide information to 
assist with management of TB in this population, 
and serve as a guide for resolving this issue. 
* Risks of TB transmission are also relevant to 
humans. Human exposure risks must clearly 
distinguish between the risks for those working 
with and handling elephants (occupational health), 
and health risks for members of the public that 
are near to but not in close contact with elephants, 
particularly in open air settings. Anecdotally, 
elephant managers and veterinarians, most of 
whom are regularly tested for TB, say that the 
occupational health risks are low for elephant 
handlers working with TB infected elephants in 
the U.S. However, objective data should answer 
this question, and this will be addressed with a 
retrospective study of the occupational health 
risks that is now in progress. 
* There is still no conclusive evidence to show 
the definitive direction of TB transmission 
between humans and elephants. In humans, 
M. tuberculosis is not highly transmissible, 
even within a household. It is well understood 
in human medicine that the disease spreads 
exclusively through aerosolization; this suggests 
that the same applies to elephants and that fomite 
(i.e. from touching objects such as feed tubs) 
transmission may be minimal or nonexistent. 
Furthermore there have been no documented 
cases of members of the public becoming TB 
infected from an elephant. Therefore it appears 
that elephants with M. tuberculosis infections 
pose a very low public health risk.
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* Serology has not proven to be an effective 
diagnostic tool for TB in humans or for M. bovis 
control programs. Serology is not a part of M. 
bovis control programs for cattle in the U.S. 
Similarly, a World Health Organization (WHO) 
report (2011) on the use of serology for detection 
of active TB infection in humans indicates that 
they are not accurate or consistent predictors 
of infection. As a result, in 2012 India became 
the first country to ban TB serology diagnostic 
tests for humans, with a notification issued by 
the Ministry of Health and Family Welfare. 
Serology tests for TB in elephants, the StatPak 
and MAPIA, have been heavily promoted and 
proposed to be highly accurate. However the 
sensitivity and specificity of these tests have 
been evaluated only at the extremes of known 
non-infected and known late stage infected 
elephants. For all other elephants, the sensitivity, 
specificity, and predictive value have not been 
determined. Based on other species and anecdotal 
evidence of false positives and negatives in U.S. 
captive elephants, it is likely that the accuracy 
of serologic tests for elephants is less than is 
currently marketed. Therefore, serology results 
alone should not be the basis for classifying 
elephants as TB “positive”, and treatment based 
on serology alone can be questioned in the 
absence of supporting evidence or concerns.
 
* While there has been considerable focus 
on diagnostic tests for TB in elephants, little 
attention has been given to treatment. The 
current treatment regimen for TB in elephants 
is very costly, long term, can have severe side 
effects on the elephant being treated, and requires 
significant veterinary oversight. There is still 
insufficient identification of pathologies resulting 
from adverse anti-tuberculosis drug effects; 
optimal routes for administration of medications 
have not been clarified; and better parameters 
for evaluating treatment success (blood levels 
of drugs are currently used) have not been 
addressed. Maintaining open communication 
for updates on recent developments in human 
TB treatments is useful. A new pharmacokinetic 
study of the drugs used in treating tuberculosis in 
elephants is currently underway in the U.S, and 
resulting data will contribute to the development 
of improved treatment protocols.
 
In Asian elephant conservation, an existing and 
important concern is how to best invest resources 
to improve elephant health. Limited resources are 
available for use on broad elephant conservation 
issues, i.e. habitat protection, conflict mitigation, 
etc. While individual animal welfare needs often 
gain attention, the challenge is balancing large 
investments in individual animals’ needs as well as 
use of resources to more broadly benefit elephant 
populations. To better assess factors that limit 
the ability to address overall elephant health and 
management concerns in Asia, a study surveying 
local veterinarians was initiated to place various 
medical conditions and infrastructure needs in 
context. Rather than focus on a single disease, as 
discussed above, the survey is intended to address 
all health and management concerns that impact 
captive and free-ranging elephant populations in 
Asia. Currently, almost fifty surveys from most 
of the Asian elephant range countries are being 
analyzed, and results will be published. Given the 
many challenges facing elephants in Asian range 
countries, such as habitat loss, human-elephant 
conflict, and other factors that increase elephant 
mortality rates and decrease reproduction, this 
survey will serve as a starting point for identifying 
resource investments that will provide the most 
population benefit. This is analogous to investing 
resources into preventive care and common 
diseases in human populations, rather than into 
uncommon but expensive diseases, to achieve the 
greatest benefit to the population with existing 
resources. Consequently, this survey’s broad-
based approach is critical for placing potential 
health risks in perspective, and identifying 
strategies that will effectively improve the health 
and welfare of elephants in Asia. 
When addressing elephant health, in particular 
where it impacts conservation strategies, we 
encourage the conservation community to 
carefully assess all of the factors that contribute 
to the development of diseases, and objectively 
and transparently evaluate the relative risks and 
allocation of resources. We anticipate that these 
aforementioned studies will not only clarify 
appropriate strategies for addressing TB concerns 
in elephants, but also identify the best ways to 
invest existing resources to truly benefit Asian 
elephant health and conservation.
